Breaking News

CRA Holdings Acquires Radiant Research

November 9, 2012

Expands patient access for trials

CRA Holdings has acquired Radiant Research, a patient recruitment firm. CRA also owns Clinical Research Advantage (CRA) and plans to combine the companies under the same investment portfolio that will have 57 sites with more than 550 research professionals. The combined companies will continue to function under their respective names but will integrate and streamline certain operations.
 
Radiant Research focuses on recruitment for common and chronic conditions from the general population. Radiant specializes in trials that require large numbers of subjects, or complex trials that require specialized equipment or procedures. CRA recruits 85% or more participants from investigators' private practices, allowing the company to focus on trials where disease-state management is required.  
 
"The Radiant platform will facilitate faster expansion of our model by utilizing the Radiant sites to help launch practice-based satellite locations in the cities where Radiant already has sites. We have grown CRA from seven to 37 sites in the last five years. In order for us to achieve our goal of 80 or 90 sites in the manner we have been doing would take us at least another five years. The Radiant acquisition will be the catalyst for much faster growth in the next 12 months," said Mark Hanley, chief executive officer of CRA.
 
"By combining the models under one umbrella, we will be able to conduct almost every type of trial, be it point of care or studies more appropriate for a stand-alone research facility," said Julie McHugh, chief executive officer of Radiant Research. "We have been looking for a partner that has a shared vision for growth without any sacrifice in quality. In CRA, we have found that partner."

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research